Lin Cai-Shi, He Meng-Qi, An Meng-Ying, Zhao Qi-Hang, Zhang Zhou-Hang, Deng Ke-Yu, Ai Yongjian, Xin Hong-Bo
The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330088, P. R. China.
State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, P. R. China.
Small. 2024 Dec;20(51):e2403313. doi: 10.1002/smll.202403313. Epub 2024 Oct 8.
Hepatic ischemia-reperfusion injury (IRI) is a severe complication that occurs in the process of liver transplantation, hepatectomy, and other end-stage liver disease surgery, often resulting in the failure of surgery operation and even patient death. Currently, there is no effective way to prevent hepatic IRI clinically. Here, it is reported that the ultra-small copper-based multienzyme-like nanoparticles with catalase-like (CAT-like) and superoxide dismutase-like (SOD-like) catalytic activities significantly scavenge the surge-generated endogenous reactive oxygen species (ROS) and effectively protects hepatic IRI. Density functional theory calculations confirm that the nanoparticles efficiently scavenge ROS through their synergistic effects of the ultra-small copper SOD-like activity and manganese dioxides CAT-like activity. Furthermore, the results show that the biocompatible CMP NPs significantly protected hepatocytes from IRI in vitro and in vivo. Importantly, their therapeutic effect is much stronger than that of N-acetylcysteamine acid (NAC), an FDA-approved antioxidative drug. Finally, it is demonstrated that the protective effects of CMP NPs on hepatic IRI are related to suppressing inflammation and hepatocytic apoptosis and maintaining endothelial functions through scavenging ROS in liver tissues. The study can provide insight into the development of next-generation nanomedicines for scavenging ROS.
肝缺血再灌注损伤(IRI)是肝移植、肝切除术及其他终末期肝病手术过程中发生的一种严重并发症,常导致手术失败甚至患者死亡。目前临床上尚无有效的方法预防肝IRI。在此,有报道称具有过氧化氢酶样(CAT样)和超氧化物歧化酶样(SOD样)催化活性的超小铜基多酶样纳米颗粒可显著清除激增产生的内源性活性氧(ROS),并有效保护肝IRI。密度泛函理论计算证实,这些纳米颗粒通过其超小铜SOD样活性和二氧化锰CAT样活性的协同作用有效清除ROS。此外,结果表明生物相容性CMP纳米颗粒在体外和体内均能显著保护肝细胞免受IRI损伤。重要的是,它们的治疗效果比美国食品药品监督管理局(FDA)批准的抗氧化药物N-乙酰半胱氨酸(NAC)要强得多。最后,证明CMP纳米颗粒对肝IRI的保护作用与通过清除肝组织中的ROS来抑制炎症和肝细胞凋亡以及维持内皮功能有关。该研究可为开发下一代清除ROS的纳米药物提供思路。